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Dosimetry and Risk Estimates of Radioiodine 
Therapy for Large, Multinodular Goiters
Dyde A.K.C. Huysmans, Wilhelmina C.A.M. Buijs, Maijo T.P. van de Ven, Wim J.M. van den Broek,
Peter W.C. ICloppenborg, Ad R.M.M. Hermus and Frans H.M. Corstens
Department o f  Nuclear Medicine and Department o f  Endocrinology, University Hospital Nijmegen St. Radboud, Nijmegen, 
The Netherlands
In patients with a large, multinodular goiter (>100 g), radiation 
absorbed doses in the thyroid, surrounding tissues and remainder of 
the body were estimated after therapeutic administration o f1311(3.7 
MBq or 100 /xCi/g of thyroid tissue retained at 24 hr). Methods: 
Thermoluminescent dosimeter (TLD) measurements were per­
formed on 23 patients (12 euthyroid and 11 hyperthyroid; thyroid 
weight 222 ± 72 g; 2.1 ± 0.9 GBq 1311) on the skin over the thyroid, 
over the submandibular gland and over the parotid gland. Thyroid 
radioactivity measurements were done daily in 6 euthyroid and 6 
hyperthyroid patients (thyroid weight 204 ± 69 g; 1.9 ± 0.9 GBq 
1311). An iodine biokinetic model and the MIRD methodology were 
used to estimate absorbed doses in organs. Cancer risks were 
calculated using ICRP Publication 60. Results: Cumulated ab­
sorbed doses on the skin (TLD measurements) were 4.2 ± 1.4 Gy 
(thyroid), 1.2 ± 0.6 Gy (submandibular) and 0.4 ± 0.2 Gy (parotid). All 
these values were significantly correlated with the amount of radio­
iodine retained in the thyroid at 24 hr (euthyroid versus hyper thy raid 
not significant). Absorbed doses in the thyroid of 94 ± 25 Gy for 
euthyroid and 93 ± 17 Gy for hyperthyroid patients were calculated 
(thyroid radioactivity measurements). Extrathyroidal absorbed doses 
(means of 12 patients) were 0.88 Gy in the urinary bladder, 0.57 Gy 
in the small intestine, 0.38 Gy in the stomach, and ranged from 0.05 
to 0.30 Gy in other organs (euthyroid versus hyperthyroid not 
significant). A 1.6% life-time risk of development of cancer outside 
the thyroid gland was calculated. When applied to people of 65 yr 
and older the estimated risk is approximately 0.5%. Conclusion: 
These data may help in choosing the treatment regimen for individ­
ual patients with a large, multinodular goiter, who have to be treated 
for hyperthyroidism or compressive problems. In younger patients, 
surgery may be preferred. However, for elderly patients and patients 
with cardiopulmonary disease, the advantages of non invasive radio­
iodine treatment will outweight the life-time risk of this mode of 
therapy.
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S urgery  is standard therapy for a patient with a large, toxic or 
nontoxic, compressive goiter. However, it is not without risk, 
especially in elderly patients with cardiopulmonary disease 
(1-3). Radioiodine, a widely accepted treatment for patients 
with toxic, noncompressive goiters, is an alternative for these 
patients. In a recent study, we have shown that radioiodine 
therapy can induce an average reduction in thyroid volume of 
40% after 1 yr and a significant widening of the tracheal lumen 
in patients with a large, compressive mutinodular goiter (4). 
However, reluctance to treat these patients with radioiodine 
may be due to a concern for excessive radiation absorbed doses. 
Many commonly used dosage schedules for radioiodine therapy
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are aimed at delivering a certain amount of radioiodine per 
gram of thyroid tissue retained in the thyroid gland at 24 hr, The 
use o f such a dosage schedule implies that large amounts of 
radioiodine are administered to patients with a large, nodular 
goiter.
The present study is focused on the dosimetric aspects of 
radioiodine therapy in patients with large goiters. We have 
estimated absorbed doses in the thyroid, in tissues directly near 
the thyroid and in tissues and organs in the remainder of the 
body after therapeutic administration o f radioiodine in hyper­
thyroid and in euthyroid patients with large, multinodular 
goiters. Thermoluminescent dosimetry was used to estimate the 
radiation burden of tissues directly near the thyroid gland. 
Estimations o f absorbed doses in the thyroid and in the 
remainder o f the body were, made using thyroid radioactivity 
measurements and a model o f iodine kinetics in the body as 
described by Robertson and G om an  (J). Risks o f radiation- 
induced cancer were assessed based on the 1990 Recommen­
dations of the International Commission on Radiological Pro­
tection (6 ).
MATERIALS AND METHODS 
Patients and Radioiodine Treatment
Twenty-three consecutive patients with a multinodular goiter of 
more than 100 g, as estimated from palpation and planar thyroid 
scintigraphy (7), were treated with radio iodine. The diagnosis of 
multinodular goiter was based on the presence of one or more 
thyroid nodules at palpation and an irregular distribtuion of [123I] 
or [131I]sodium iodide on a thyroid scan. Patients with a solitary hot 
nodule were excluded. In the 11 patients with toxic multinodular 
goiter the primary aim of radio iodine therapy was to treat hyper­
thyroidism. Eight of them had compressive symtpoms. All euthy­
roid patients (n =  12) sought treatment for compressive symptoms. 
In these patients, radioiodine therapy was chosen because of 
contraindications for surgery (n =  8; mainly because of cardiopul­
monary disease) or refusal of the patient to undergo surgery (n = 
4). Patients were classified as euthyroid when they had serum-free 
thyroxine (fT4) and tri-iodothyronine (T3) levels within the normal 
range of our laboratory (fT4, 9.0™17.0 pmole/liter; T3, 1.5-3.5 
nmole/liter) and were not taking antithyroid or thyromimetic drugs. 
The serum level of thyroid stimulating hormone (TSH) was 
subnormal (<0.4 mU/liter) in seven patients. In two euthyroid 
patients, prior TSH suppressive treatment with L-thyroxine had 
failed to diminish goiter size. L-thyroxine had been withdrawn 2 
mo before radioiodine treatment in these patients. All hyperthyroid 
patients used methimazole and L-thyroxine. They did not receive 
methimazole for 3 days before and 3 days after radioiodine therapy. 
Radioiodine was given as a single intravenous dose on an in-patient 
basis. The administered activity was aimed at delivering 3.7 MBq 
(100 fxCi) of 13ll per gram of thyroid tissue retained at 24 hr, 
according to the following formula (8):
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A dm inistered ac tiv ity  (GBq)
_  thyroid weight (g) X 0.37
24-hr thyroid radioactive iodide uptake (%)
Thyroid rad io ac tiv e  io d id e  up take  (RAIU) was m easu red  24 hr 
after oral ingestion of 7.4 MBq (200 ( i d )  13 *1 (normal range 
10-59%). Since gastrointestinal absorption of radioiodine is rapid 
and complete it is unlikely that the oral route of administration of 
the diagnostic activity may result in different values for 24-hr 
RAIU compared with the intravenous route. The thyroid weight 
was estim ated  from the p lan im e tric  surface on a rectilinear thyroid 
scintigram using the formula of Doering and Kramer: thyroid 
weight (g) =  0.326 X (surface in cm2)3/2 (7 ).
Thermoluminescent Dosimeter Measurements and 
Dosimetric Calculations
Thermoluminescent dosimeter (TLD) measurements were per­
formed following the therapeutic administration of radioiodine in 
12 euthyroid and 11 hyperthyroid patients. Two freshly annealed 
TLDs sealed in a thin polyethylene bag were positioned with 
sticking plaster on the skin on each of the following three locations: 
directly over the thyroid gland, over the submandibular gland and 
over the parotid gland. The TLD on the thyroid gland was placed 
over the center of the most prominent nodule, which was checked 
not to be cold on thyroid scintigraphy. Distances between the TLDs 
on the salivary glands and the palpated ipsilateral top of the thyroid 
were measured. The TLDs were left in position for 24 hr and 
replaced daily for 5 to 15 days after the therapeutic administration 
of radioiodine. After preannealing, TLDs were read for light output 
(in nanocoulombs) on a TLD reader under dry N2. The calibration 
factor of TLDs for the gamma irradiation of 1311, as checked in 
vitro, was 100 microgray per nanocoulomb (¿¿Gy/nC). Data from a 
previous study (4) in patients with a large multinodular goiter (nine 
of whom also participated in the present study) suggest that the 
distance between the surface of the thyroid and the surface of the 
skin, as determined from axial magnetic resonance imaging slices, 
was more than 5 mm. Therefore, the contribution of beta irradiation 
was assumed to be negligible on the surface of the skin.
TLD measured values from Day 2 onward were fitted monoex- 
ponentially and extrapolated to infinity. The measured values and 
the integral of the extrapolated function were summed for each 
location in order to determine cumulated absorbed doses on the 
skin (Gy).
Thyroid Radioactivity Measurements, Dosimetric 
Calculations and Risk Estimates
In six euthyroid and six hyperthyroid patients, thyroid radioac­
tivity measurements were performed every 24 hr after the thera­
peutic administration of radioiodine for 7 to 14 days. A 2 in X 2 in 
Nal (TI) detector with a diverged-lead collimator connected with 
an analyzer (type ST 6, Nuclear Enterprises, Reading, UK) was 
used. The collimator was provided with a lead collimator dia­
phragm complying with recommendations of the International 
Atomic Energy Agency (neck-to-detector distance 26 cm). An 
18-mm thick lead shield was placed in front of the detector in order 
to reduce the count rate and avoid dead-time effects. Measurements 
were corrected for a 10-ml test tube standard with a known activity 
of 1311 and all values were corrected for background radioactivity 
in the room and for physical decay. The mean of three measure­
ments of I -min duration was used.
Thyroid radioactivity measurements were implemented in a 
simplified model for iodine biokinetics as described by Robertson 
and Gorman, diagrammatic ally represented in Figure 1 (5). In this 
model, intravenously administered radioiodide is removed from the 
extrathyroidal iodide compartment by excretion into the urinary
FIGURE 1. Simplified model for iodine biokinetics (5). r, = 0.072 hr-1 based 
on a normal renal function. r2 and r3 were calculated from thyroid radioactivity 
measurements. A total of 15% of the extrathyroidal iodide compartment is 
located in the stomach; 17% in the small intestine; and 40% of the 
extrathyroidal thyroid hormone compartment is located in the liver. The 
remaining parts are evenly distributed throughout the body.
iodide compartment, with fractional removal rate r t (in hr” 1), and 
by uptake into the thyroid, with fractional uptake rate r2 (in hr-1). 
In the thyroid radioiodide is incorporated in thyrogiobulin. A 24-hr 
delay in the secretion of radioiodinated thyroid hormones is 
assumed (5). After that time, the loss of radioactivity from the 
thyroid into the compartment of extrathyroidal radioiodinated 
thyroid hormone is indicated by the fractional secretion rate r3 (in 
hr“ 1). Degradation of the radioiodinated thyroid hormone is 
assumed to be instantaneous (5). The rate of (renal) excretion of 
radioiodide resulting from thyroid hormone degradation is sup­
posed to equal that of the administered iodide. The model does not 
take into account re-uptake into the thyroid of radioiodide resulting 
from thyroid hormone degradation outside the thyroid, A system of 
differential equations, using the three rate constants, r h r2 and r3, 
and the physical decay constant A (0.00359 hr-1) describes the 
rates of changes of radioactivity in the four compartments. The 
solutions of the differential equations describe the fractional 
activities, i.e., the fractions of the administered activity at time t in 
each of the compartments. These fractional activities are integrated 
in order to obtain the cumulated (time-integrated) fractional activ­
ities (cumulated activity per MBq of administered activity in 
MBq * h/MBq, i.e., in h; this parameter is also referred to as 
residence time) in each of the four compartments. Time-integrated 
activities resulting from the total administered activities of radio­
iodine are referred to as cumulated activities (in MBq • hr).
Serum creatinine levels were within the normal range in all 
patients. Therefore, an xl of 0.072 hr-1 based on a normal renal 
function was assumed for all patients in our study (9). The r2 was 
calculated from the radioactivity measurement at 24 hr and from 
(24-hr RAIU -  RAIUniax [1 -  e~24(ri+r2)] in which RAIUmax is the 
theoretical maximal thyroid radioactive iodide uptake). Thyroid 
radioactivity measurements from Day 2 onward (corrected for 
physical decay) were fitted as a mo no exponential function. The 
rate constant of this function was used as r3.
In the biokinetic model of Robertson and Gorman (5), the 
extrathyroidal iodide and extrathyroidal thyroid hormone compart­
ments are combined and assumed to be evenly distributed through­
out the body, outside the thyroid and urinary bladder. We made the 
following amendments to the biokinetic model based on data in 
MIRD Pamphlet No. 12 and MIRD Report No. 5 (10,11). Of the 
extrathyroidal iodide compartment 15% was assumed to be located 
in the stomach and 17% in the small intestine. Of the extrathyroidal
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hyroicl hormone compartment, 40% was assumed to be located in 
the liver (and, proportional to the weight of the liver, 2.4% of the 
iodide compartment). Corresponding percentages of the residence 
times in the extrathyroidal iodide and thyroid homione compart­
ments were asigned to the stomach, small intestine and liver. The 
remaining parts of these residence times were assigned to the total 
body (i.e., evenly distributed throughout the body outside the 
thyroid, urinary bladder, stomach, small intestine and liver). To 
obtain the residence time in the urinary bladder, the cumulated 
fractional activity in the urine was corrected for voiding with a 
voiding interval of 4 hr (5). Only the urine that enters the bladder 
during a voiding interval is used in calculating the fractional 
activity in the bladder during that interval. A constant bladder 
volume was assumed.
Radiation absorbed doses (1 Gy = 100 rad) in organs were 
calculated using the MIRD method with tabulated S-values for 
adults (i.e., the mean radiation absorbed dose in a target organ per 
unit cumulated activity in a source organ) (12). The calculated 
residence times in the source organs thyroid, urinary bladder, 
stomach, small intestine and total body were entered in the 
MIRDOSE2 computer program (Oak Ridge, TN). In all patients, 
absorbed doses in the thyroid, as calculated in the MIRDOSE2 
program, were corrected for differences in thyroid mass between 
Standard Man (12) and patients using the Standard Man thyroid 
mass (20 g)-to-patient thyroid mass ratio and for the increasing 
absorbed fraction of beta particles and photons with increasing 
thyroid volume, based on S-values for 13[l uniformly distributed in 
spheres of increasing volumes of 1 g/cm3 density (13).
ICRP Publication 60 (6) was used to estimate the risk of 
radiation-induced cancer in our patients. In ICRP 60, absorbed 
doses weighted by a radiation factor (which is 1 for radiopharma­
ceuticals) are called equivalent doses (H; in Sievert, Sv; 1 Sv = 
100 rem) (6). The sum of the fatal cancer risk (estimated at 5%/Sv 
whole-body irradiation), nonfatal cancer risk (estimated at 1%/Sv 
whole-body irradiation) and the risk of severe hereditary effects 
(estimated at 1.3%/Sv whole-body irradiation) is 7.3% per sievert 
total body irradiation and is called the total health detriment. The 
total health detriment is a measure of the adverse health effects that 
would eventually be experienced by an exposed group and its 
descendants as a result of the group’s exposure to a radiation 
source (6). These probability coefficients (in %/Sv) are applicable 
to equivalent doses resulting from absorbed doses below 0.2 Gy 
and from higher absorbed doses when the dose rate is less than 0,1 
Gy per hour. The relative importance of each of the various organs 
in contributing to this detriment (14) is expressed by its weighting 
factor (WT) (6 ). The detriment for each organ is expressed as 
WT X 7.3%/Sv organ dose. The fatal and nonfatal cancer risk is 
extracted from the total health detriment by excluding 90% of the 
weighting factor for the gonads because this weighting factor 
applies for 90% to the risk of severe hereditary effects and for only 
10% to the gonadal (especially ovarian) cancer risk. For other 
organs the weighting factor only applies to the cancer risk. 
Furthermore, the values for tissue weighting factors were used to 
determine the effective dose which is the sum of the weighted 
equivalent doses in all the tissues and organs of the body (effective 
dose =  SW T X Ht ) (<5). Only the contributions of the organs and 
tissues outside the thyroid were summed, because equivalent and 
effective doses are not applicable to high doses as received by the 
thyroid during radioiodine therapy.
Statistical Analyses
The mean values ± s.d. are given. Statistical analyses were done 
using the Mann-Whitney U test for unpaired observations (p-values 
denoted as p), the Wilcoxon sign-rank test for paired observations
(p-values denoted as p*) and the Spearman rank correlation test 
(p-values denoted as p**). The level of significance was 0.05.
RESULTS
No increases o f compressive symptoms were observed after 
radioiodine treatment. One hyperthyroid patient complained 
about some further swelling o f his goiter from the third until the 
sixth day after radioiodine therapy. For detailed information on 
the effectiveness o f radioiodine treatment for large, multinod- 
ular goiters, the reader is referred to a recently published study 
from our group (4 \  in which a 20% to 70% reduction of thyroid 
volume (mean 40%) and significant decompression of the 
trachea was demonstrated using MRI 1 yr after radioiodine 
treatment. In the present group of patients no MRI measure­
ments of thyroid volume reduction and decompression of vital 
structures were done.
Thermoluminescent Dosimeter Measrements
Table 1 shows patient characteristics and data o f TLD 
measurements on the skin over the thyroid, the submandibular 
and the parotid gland in 12 euthyroid and 11 hyperthyroid 
patients. The thyroid weight was similar in both groups of 
patients. The 24-hr thyroid radioactive iodide uptake was 
significantly lower in euthyroid patients (p <  0.02). The total 
administered activity was higher in euthyroid than in hyperthy­
roid patients, although the difference was not significant. No 
significant differences in cumulated absorbed doses between 
euthyroid and hyperthyroid patients were observed at any of the 
three lcoations on the skin.
Cumulated absorbed doses at all three locations were signif­
icantly correlated with the total activity retained in the thyroid 
at 24 hr (administered activity X 24-hr RAIU) (r =  0.642, p** 
<  0.001 for the thyroid location; r =  0.696, p** <  0.001 for the 
submandibular location; r =  0.579, p** <  0.005 for the parotid 
location) (Fig. 2). The correlation o f the cumulated absorbed 
dose on the skin with the total administered activity was only 
significant for the location over the thyroid gland (r =  0.557, 
p** <  0.01) and no correlation of cumulated absorbed doses on 
the skin with 24-hr RAIU was found (p** >  0.1). The effective 
half-time of 13 !I in the thyroid gland, as measured by TLDs, 
was significantly higher for euthyroid patients (6.1 ±  0.8 days) 
than for hyperthyroid patients (5.5 ± 0 . 7  days) (p <  0.03).
Thyroid Radioactivity Measurements, Dosimetric 
Calculations and Risk Estimates
Table 2 shows patient characteristics and data o f thyroid 
radioactivity measurements in six euthyroid and six hyperthy­
roid patients. The thyroid weight was similar for euthyroid and 
hyperthyroid patients. There were no significant differences in 
administered activity, 24-hr RAIU or effective half-time o f 1311 
in the thyroid (thyroid radioactivity measurements) between 
both groups. Residence times in source organs, as calculated 
from thyroid radioactivity measurements and the aforemen­
tioned biokinetic model (5) with modifications (10,11), did not 
differ significantly between euthyroid and hyperthyroid pa­
tients, except for the residence time in the liver, which was 
significantly higher for hyperthyroid patients (p <  0.03) (Table 
2). Effective half-times o f 131I in the thyroid resulting from 
thyroid radioactivity measurements were not'significantly dif­
ferent from those measured with TLDs in the same 12 patients 
(Wilcoxon sign-rank test, p* =  0.7). Moreover, a highly 
significant correlation was found between the cumulated activ­
ity (in MBq * hr) in the thyroid and the cumulated absorbed 
dose on the skin overlying the thyroid as measured with TLDs 
in the same 12 patients (r =  0.748, p** <  0.01).
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TABLE 1
Patient Characteristics and Dta of TLD Measurements after Radioiodine Treatment of Euthyroid and Hyperthyroid Patients with Large 
Muitinodular Goiters (>100 g)
Number of patients 
Age (yr)
Female:Male ratio
Serum level of thyroid-stimulating hormone*
Serum level of free thyroxine*
Serum level of total triiodothyronine*
Thyroid weight (g)
24-hr RAIU { % )
Administered activity o f1311 (GBq)
Cumulated dose on skin thyroid (Gy)
Cumulated dose on skin submandibular gland (Gy) 
Cumulated dose on skin parotid gland (Gy) 
Distance thyroid-submandibular gland (cm) 
Distance thyroid-parotid gland (cm)
TLD measured effective half-time thyroid (days)
Euthyroid 
12
62 ±12 (44-81)
11:1
0.33 ±0.39 (<0.01-1.20) 
11.9 ±1.9 (6.9-14.2)
2.2 ±0.5 (1.6-3.3)
221 ± 81 (122-351)
36 ±11 (21-56)
2.3 ± 0.8(1.2-4.0)
4.4 ± 1.5 (2.4-7.2)
1.2 ± 0.6 (0.5-2.4)
0.3 ± 0.1 (0.2-0.8)
4.7 ± 2.0 (2.S-7.5)
10.7 ±1.8 (8.5-13.5)
6.1 ± 0.8 (4.4-7,3)
Hyperthyroid 
11
71 ± 8 (57-82)
8:3
(on thyroid medication) 
(on thyroid medication) 
(on thyroid medication) 
224 ± 65 (130-312) 
51 ± 14 (32-88)t  
1.8 ± 0,8 (0.8—3.3) 
4.1 ± 1.4 (2.0-6,3)
1.3 ± 0.6 (0,5-2.0) 
0.4 ± 0.1 (0.2-0.7)
4.3 ± 1.7 (2.S-7.5) 
10.5 ±2.0 (8.0-13.5)
5.5 ± 0.7 (4.2-6.5)*
The mean values ± s.d. are given; ranges are given in parentheses.
*Normal ranges: thyroid-stimulating hormone, 0.4-4.0 mU/l; free thyroxine 9.0-17.0 pmole/l; total triiodothyronine, 1.5-3.5 nmole/liter. 
fp < 0.02 euthyroid versus hyperthyroid patients.
*p < 0.03 euthyroid versus hyperthyroid patients.
Table 3 shows the calculated absorbed doses in the tissues the stomach and small intestine, inverse correlations were found
and organs for which a tissue weighting factor has been 
determined (6 ), expressed as dose per unit o f administered 
radioiodine (in mGy/MBq) and as dose resulting from the total 
administered activities o f radioiodine (in Gy), Outside the 
thyroid gland the highest absorbed doses per MBq of adminis­
tered 1311 were calculated for the urinary bladder, followed by
FIGURE 2. Cumulated absorbed 
doses on the skin over the thyroid
(A), over the submandibular gland
(B) and over the parotid gland (C) 
plotted against the total radioactivi­
ties retained in the thyroid at 24 hr 
(administered activity x  24-hr 
RAIU(%)/100).
A
I
1
C
3
a.o
6.0 - -
4.0 - -
2.0
0.0
roO,642 
p*’<0.001
«
»
0.0 0.5 1.0 1.5
B
4.0
>No
S 3.0 S
Thyroid radioactivity at 24 h {GBq)
2.0 - -
1.0 - -
0.0
r-0.6 96 
p"<0.001
0.0 0.5 1.0 1.5
Thyroid radioactivity at 24 h (GBq)
1.0
0.8
0.5 - -
0.3 - -
0.0
raO.579
p**<0.005
0.0 0.5 1.0 1.5
Thyroid radioactivity at 24 h (GBq)
between the 24-hr RAIU and the absorbed doses per MBq in the 
stomach (r =  -0 .9 7 , p <  0.001), small intestine (r =  -0 .98 , 
p <  0,001) and urinary bladder (r =  -0 ,8 5 , p <  0.01). The 
absorbed dose in the liver was positively correlated with the 
24-hr RAIU (r =  0.83, p <  0.001). The absorbed dose in the 
liver (mGy/MBq) was significantly higher in hyperthyroid than 
in euthyroid patients (p <  0.03). There were no other significant 
differences for organ doses between euthyroid and hyperthyroid 
patients.
Extrathyroidal doses resulting from the total administered 
activities ranged between 0,06 Gy (testes) and 1.06 Gy (urinary 
bladder) in euthyroid patients and between 0.04 Gy (testes) and 
0,71 Gy (urinary bladder) in hyperthyroid patients (average 
values o f six patients in both groups). No significant correla­
tions o f absorbed doses (Gy) with 24-hr RAIU were found. The 
mean absorbed doses in most tissues were about similar for 
euthyroid and hyperthyroid patients (p >  0,3). The mean 
absorbed doses in stomach, small intestine and urinary bladder 
were higher for euthyroid than for hyperthyroid patients. 
However, these differences were not significant.
The effective dose for the combined organs and tissues outside 
the thyroid gland was not significantly different for euthyroid 
(0.27 ±  0.14 Sv) and hyperthyroid patients (0.19 ±  0.07 Sv). 
Using the total health detriment o f 7.3%/Sv given in ICRP 
Publication 60 (6) and excluding the risk of severe hereditary 
effects, the life-time risk o f cancer for the combined organs and 
tissues outside the thyroid can be estimated as 1,8% ±  1.0% for 
euthyroid patients and 1.3% ±  0.5% for hyperthyroid patients 
in the present study (difference euthyroid versus hyperthyroid 
not significant). A total health detriment of 7.3%/Sv is, how­
ever, an average for a population of all ages. For people aged 45 
yr or older, the probability of radiation-induced cancer is less 
than half of the average for a population of all ages and for 
people of 65 yr and older it is only about one-third of the average 
(6,14,15). Because 8 of 12 patients in the present study were older 
than 65 yr and only one patient was younger than 60 yr an estimate 
of approximately 0.5% life-time risk of cancer (outside the thyroid 
gland) seems more appropriate.
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TABLE 2
Patient Characteristics and Data of Thyroid Radioactivity Measurements After Radioiodine Treatment of Euthyroid and Hyperthyroid 
Patients with Large Multinoduiar Goiters (>100 g)
Number of patients 
Age (yr)
Female:Male ratio 
Thyroid weight (g)
24-hr RAIU tracer activity (%)
24-hr RAIU therapeutic activity ( % )  
Therapeutic activity o f1311 (GBq)
Effective half-time o f1311 in thyroid (days) 
Biological half-time o f1311 in thyroid (days) 
Cumulated activity thyroid (MBq hr) 
Residence time thyroid (hr)*
Residence time stomach (hr)*
Residence time small intestine (hr)* 
Residence time liver (hrf 
Residence time rest body (hr)*
Residence time urinary bladder (hr)*
Euthyroid 
6
65 ±10 (52-81)
5:1
84(126-351)
11 (21-48)
16 (17-58)
1.1 (1.2-4.0)
0.4 (5.1-6.1)
6 (14-31)
110 (67-377)
34 (37-120)
0.31 (0.84-1.62) 
0.35 (0.95-1.83) 
0.17 (0.47-0.90)
1.1 (4.9-7.6)
.2 (1.2-1.7)
203 ± 
37 ± 
37 ± 
2.2 ± 
5.7 ± 
21 ± 
160 ± 
77 ± 
1.23 ± 
1.40 ± 
0.70 ± 
6.3 ±
1.5 ±
Hyperthyroid 
6
70 ± 6 (63-80)
3:3
206 ± 59 (130-274)
51 ± 11 (35-63)*
52 ± 5 (47-59)*
1.6 ± 0.6 (0.8-2.2)
5.3 ± 0.5 (4.7-6.1)
18 ± 5  (11-25)
155 ±57(82-215)
99 ±11 (82-116)
0.9 ±0.08(0.82-1.04) 
1.09 ±0.10 (0.93-1.18) 
1.00 ±0.16 (0.71 ~1.16)§ 
5.5 ± 0.4 (5.0-6.0)
1.3 ±0.1 (1.2-1.4)
*p <  0.02 euthyroid versus hyperthyroid patients.
"^ Calculated from thyroid radioactivity measurements.
^Calculated using thyroid radioactivity measurements and the biokinetlc model of Robertson and Gorman (5) with amendments based on MIRD Pamphlet 
no. 12 (to) and MIRD Report No. 5 (11).
§p <  0.03 euthyroid versus hyperthyroid patients.
The mean values ± s.d. are given; ranges are given in parentheses.
DISCUSSION
In the present study, TLD measurements showed cumulated 
(i.e., time-integrated) radiation absorbed doses of 4.2 ±  1.4 Gy 
on the skin directly overlying the thyroid, of 1.2 ±  0.6 Gy on 
the skin over the submandibular gland and of 0.4 ±  0.2 Gy on 
the skin over the parotid gland, after therapeutic administration 
of radioiodine in patients with a large, multinoduiar goiter
(mean thyroid weight 222 ±  72 g), There were no significant 
differences between euthyroid and hyperthyroid patients. Ab­
sorbed doses at all three locations were significantly correlated 
with the amount o f radioiodine retained in the thyroid at 24 hr. 
Absorbed doses in the spinal cord must have been lower than 
the doses measured on the skin over the thyroid because the 
distance between the posterior edge of the thyroid and the spinal
TABLE 3
Radiation Absorbed Doses in Target Organs after Radioiodine Treatment of Euthyroid and Hyperthyroid Patients with a Large 
Multinoduiar Goiter (>100 g) Calculated with the MIRD Method
—  ■ ■ .—----- —------------------------- -------- -— ——^ --------------------------------------- ---------------------- - —  __ -  . ------------------------------------- rm
Absorbed dose per unit administered activity (mGy/MBq) Absorbed dose (Gy)
Target organ Euthyroid (n -  6) Hyperthyroid (n = 6) Euthyroid (n = 6) Hyperthyroid (n = 6)
Thyroid* 51 ±23 64 ± 19 94 ±25 93 ±17
Red bone marrow 0.092 ± 0.024 0.108 ±0.008 0.19 ±0.11 0.16 ±0.08
Ovaries 0.044 ± 0.008 0.039 ± 0.002 0.10 ±0.06 0.06 ± 0.02
Testes 0.025 ± 0.004 0.023 ± 0.001 0.06 ± 0.03 0.04 ± 0.01
Colon* 0.044 ± 0.008 0.038 ± 0.002 0.10 ± 0.06 0.06 ± 0.02
Lung 0.089 ± 0.028 0.107 ±0.009 0.19 ±0.11 0.17 ±0.06
Stomach 0.33 ± 0.08 0.26 ± 0.02 0.74 ± 0.49 0.41 ±0.16
Urinary bladder 0.48 ± 0.08 0.43 ± 0.03 1.06 ± 0.63 0.71 ± 0.30
Breast 0.045 ±0.010 0.051 ± 0.003 0.10 ±0.05 0.08 ± 0.03
Liver 0.078 ± .012 0.099 ±0.011* 0.17 ±0.08 0.16 ± 0.06
Skin 0.056 ± 0.015 0.066 ± 0.005 0.12 ±0.07 0.11 ±0.03
Bone surface 0.116 ±0.037 0.140 ±0.013 0.24 ±0.14 0.22 ± 0.09
Remainder5 0.085 ± 0.006 0.088 ± 0.003 0.18 ±0.09 0.14 ± 0.05
Effective dose outside 0.27 ±0.14 0.19 ±0.07
Thyroid (Sv)
The mean values ± s.d. are given.
*Thyroid absorbed doses as calculated with MIRDOSE2 are corrected for differences in thyroid mass between Standard Man [ 12) and patients using the
Standard Man thyroid mass (20 g)-to-patient thyroid mass ratio and for the increasing absorbed fraction of beta particles and photons with increasing thyroid 
voi u me.
*0.57 x  dose upper large intestine + 0.43 x  dose lower large intestine (6).
*p < 0.03 euthyroid versus hyperthyroid patients.
§Absorbed dose in the “remainder of the body” is the average dose in the following organs and tissues: adrenals, brain, upper large intestine, small
intestine, kidney, muscle, pancreas, spleen, thymus and uterus (6 ),
^ ----k. ~ — __  ________  ____  _____
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cord is considerably larger than the distance between the 
anterior edge o f the thyroid and the surface o f the skin. This 
implies that the cervical spinal cord has absorbed less than one 
tenth of the dose which in external radiation therapy is consid­
ered the threshold dose above which necrosis o f the spinal cord 
may be induced (approximately 55 Gy delivered in 30 fractions 
over 5 to 6 wk) (75). On the other hand, it is likely that in a 
number o f our patients the esophageal and tracheal mucosa at 
the level o f the thyroid gland have absorbed higher doses of 
gamma radiation than those measured with TLDs on the skin, 
because in many patients with a large goiter, thyroid tissue is 
immediately adjacent to the trachea and esophagus on the 
anterior as well as on the right and left side. However, it.is not 
to be expected that significant doses o f beta radiation have been 
absorbed in the esophageal and tracheal mucosa, because the 
maximal range of beta particles o f 13ll in tissues is 3 mm and 
the average range only 0.3 mm.
The significant correlation between absorbed doses on the 
skin overlying the salivary glands and the amount of radioio­
dine in the thyroid at 24 hr suggests that these doses were for a 
large part caused by gamma radiation from radioiodine in the 
thyroid gland. Absorbed doses within the salivary glands will 
have been higher than those measured on the skin, because of 
beta irradiation from radioiodide concentrated in these glands. 
The methods we used do not permit further quantification of the 
absorbed doses within the salivary glands.
In accordance with earlier studies (16,17) TLD measure­
ments proved an effective method o f  monitoring effective 
half-times o f 131l in the thyroid. For this purpose TLDs may be 
applied by the patients themselves at home, thus eliminating the 
need for frequent thyroid radioactivity measurements in the 
clinic (77). Our TLD measurements in 23 patients showed a 
small but significant difference in effective half-times of l31I in 
the thyroid between euthyroid and hyperthyroid patients (6.1 ±  
0.8 days and 5.5 ±  0.7 days, respectively). Thyroid radioactiv­
ity measurements with a N al detector in 12 patients showed 
similar effective half-times o f 13lI in the thyroid. Using this 
method, the difference between euthyroid and hyperthyroid 
patients was not significant (5.7 ±  0.4 days and 5.3 ±  0.5 days, 
respectively). The effective half-time of about 5.5 days for 
hyperthyroid patients found in our study is comparable to other 
reports on hyperthyroid patients (18-21).  However, the ob­
served effective half-times in hyperthyroid as well as in 
euthyroid patients are considerably lower than those reported in 
the dose estimate reports for radioiodine in ICRP Publication 53 
(7.3 days) (22) and MIRD Report No. 5 (6.9 days) (11) which 
apply to tracer doses o f 1311 in euthyroid adults. The fast release 
o f radioiodine from the thyroid found in our study may have 
been caused by radiation-induced damage to thyroid cells from 
therapeutic activities of radioiodine (5,21,23) or may be related 
to the state o f iodine sufficiency. In view o f the small difference 
between euthyroid and hyperthyroid patients, the elimination 
rate o f a therapeutic activity o f 13 ll from the thyroid appears to 
be less dependent on the functional state o f the thyroid at the 
time of therapy.
A highly significant correlation between the cumulated dose 
on the skin overlying the thyroid and the cumulated activity 
within the thyroid as measured with a N al detector was found. 
However, TLD measurements depend too much on thyroid 
mass, depth and geometry to warrant their use in estimating 
absorbed doses within the thyroid (24). Therefore, we used 
radioactivity measurements with a N al detector to estimate 
absorbed doses in the thyroid. The absorbed dose in the thyroid 
of approximately 95 Gy for both euthyroid and hyperthyroid 
patients, found in our study, is in the lower range o f  doses
commonly used for the treatment o f toxic multinoduiar goiter 
(80-200 Gy) (25-28).  This is explained by the combination of 
a relatively low administered activity per gram of thyroid tissue 
and a short effective half-time in the thyroid. Uncertainty in our 
calculations of thyroid absorbed doses is caused by the inaccu­
racy of thyroid weight estimations by planar scintigraphy 
(29,30). Furthermore, the calculated absorbed dose in the 
thyroid is an average value for the whole thyroid gland. In a 
nodular goiter, considerable regional differences in absorbed 
doses are caused by inhomogeneous radioiodine uptake within 
the goiter.
Using radioactivity measurements and the biokinetic model 
o f Robertson and Gorman (5), the mean values for absorbed 
doses in extrathyroidal tissues and organs ranged from 0.024 to 
0.46 mGy/MBq of administered radioiodine. Absorbed doses 
per MBq in the urinary bladder, stomach and small intestine 
were inversely correlated with 24-hr RAIU, because a larger 
uptake o f iodide into the thyroid gland reduces the residence 
time of [131I]iodide in the urinary bladder and other extrathy­
roidal organs. The liver, unlike stomach, small intestine and 
urinary bladder, is the organ where l31I incorporated in thyroid 
hormones is collected and metabolized. This was accounted for 
by assigning 40% of the extrathyroidal thyroid hormone com­
partment to the liver (10,11). This explains why the absorbed 
dose per MBq in the liver was positively correlated with the 
24-hr RAIU, which is an indicator of the synthesis of thyroid 
hormones. Furthermore, the residence time and the absorbed 
dose per MBq in the liver were significantly higher in hyper­
thyroid than in euthyroid patients, reflecting the higher metab­
olism of radioiodinated thyroid hormones in hyperthyroidism. 
However, for the absorbed doses resulting from the total 
administered activities o f radioiodine, neither significant corre­
lations with the 24-hr RAIU nor a significant difference 
between hyperthyroid and euthyroid patients were found, be­
cause in our dose calculations the total administered activity is 
inversely related with 24-hr RAIU.
The absorbed doses per MBq of administered 1311 found in 
our study are in accordance with data in the literature, obtained 
by other techniques of measurement and other biokinetic 
models (11,22,31-33). However, our patients with large, multi- 
nodular goiters and a low thyroid radioiodide uptake received 
considerably larger total activities of radioiodine than the 
amounts that are commonly used in patients with Graves’ 
disease. Therefore, extrathyroidal radiation absorbed doses (in 
Gy) were about four times as high as those reported for patients 
with Graves’ disease in the literature (5,34-37).
The risk o f induction of thyroid cancer by external radiation 
is dose dependent (38). Absorbed doses in the thyroid during 
radioiodine therapy are more than 10 times as high as doses 
reported for external radiation exposure (38). However, in 
studies with a long-term follow-up of large numbers o f patients 
treated with radioiodine for hyperthyroidism no significantly 
increased risk o f thyroid cancer was found (36,37,39,40). It has 
been suggested that high doses, as absorbed in the thyroid 
during radioiodine therapy for hyperthyroidism, lead to sub­
stantial cell killing and cell sterilization instead of the produc­
tion of carcinogenic mutations in the cell’s DNA (36,38,41). 
Although our patients with large goiters received higher total 
amounts o f radioiodine than the patients in the aforementioned 
follow-up studies (36,37,39,40) absorbed doses in the thyroid 
were similar. Therefore, an elevated risk o f thyroid cancer is not 
to be expected in these patients with a large goiter.
From studies with follow-up till 35 yr, there is no evidence 
that the overall cancer incidence and cancer mortality in 
patients with Graves’ disease treated with radioiodine are
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elevated (36,37,42,43). Literature on cancer incidences after 
radioiodine therapy relating specifically to patients with nodular 
goiter is sparse. In one study, a slightly elevated overall cancer 
incidence was reported in patients with toxic nodular goiter 
treated with radioiodine (average administered activity 700 
MBq or 19 mCi), possibly related to higher administered 
activities than in patients with Graves’ disease (average admin­
istered activity 360 MBq or 10 mCi) (36). This is still to be 
confirmed in other studies. With respect to the incidence of 
cancers of individual extrathyroidal organs and tissues in 
patients treated with radioiodine for hyperthyroidism (Graves’ 
disease or nodular goiter), the risk of leukemia appears not to be 
elevated (44-46).  The risk of cancer of the stomach may be 
slightly increased (36,37). In some studies, the incidences of 
bladder cancer and of breast cancer have been reported to be 
increased (45,47,48). However, these findings have not been 
confirmed by other studies (36,37,45).
In our study, patients with a large, multinoduiar goiter were 
treated with considerably larger amounts o f radioiodine (1900 
MBq or 51 mCi on average) than the average doses adminis­
tered in the aforementioned studies. Using a total health 
detriment of 7.3%/Sv for a population of all ages (6) and 
excluding the risk o f severe hereditary effects, we calculated a 
1.6% life-time risk o f fatal and nonfatal cancer for the combined 
organs outside the thyroid. By comparison, the life-time risk of 
fatal cancer for an unexposed population of all ages is approx­
imately 20% (49) and this percentage is of course higher when 
nonfatal cancers are included In older people, the full incidence 
of radiation-induced cancer is not expressed because their life 
expectancy is shorter than the average latent period (14,49). 
Accordingly, we calculated a lower risk (0.5%) for people over 
65 yr of age. This figure is in the same order of magnitude as 
that reported for the surgical mortality of subtotal thyroidec­
tomy (1,3). The risks of surgery are of course higher in elderly 
patients, in patients with a large goiter and in those with 
cardiopulmonary disease (2). Furthermore, the morbidity of 
thyroid surgery, including nonfatal complications, is consider­
ably larger (1-3).
Until now, no follow-up data on cancer incidence in patients 
with a large goiter treated with high doses of radioiodine are 
available. It has to be stressed that the risk o f radioiodine 
therapy calculated in our study is only a rough estimate o f risk. 
Because radiation risk estimates are predominantly based on 
epidemiological data of populations after instantaneous external 
irradiation (mostly survivors of the atomic bombs) they com­
prise a number of uncertainties, e.g., uncertainties inherent in 
dose estimations, in the selection of an appropriate risk model, 
and in the applicability o f risk estimates measured in one 
population to other exposed groups (6,49,50). In the case of 
radioiodine therapy the cancer risk may be overestimated 
because the carcinogenic effectiveness per gray of gamma and 
beta radiation is reduced at the low dose rates which are 
delivered by the internally deposited 1311 with its physical 
half-time of 8 days (49).
disease, the profits o f noninvasive radioiodine treatment will 
outweigh the life-time risk o f this mode o f therapy.
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CONCLUSION
The estimated risks of both surgery and radioiodine should be 
carefully weighed in all patients with a large, multinoduiar 
goiter who have to be treated for hyperthyroidism or compres­
sive problems. In younger patients surgery may be preferred, 
especially when the amount of radioiodine to be administered, 
as calculated from a radioiodine tracer study, is high or 
whenever there is any suspicion of thyroid malignancy. How­
ever, for elderly patients and patients with cardiopulmonary
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Radiation Dose from Breastfeeding Following 
Administration of Thallium-201
R. Eugene Johnston, Suresh K. Mukherji, J. Randolph Perry and Michael G. Stabin
Department o f  Radiology), University o f  North Carolina School o f  Medicine, Chapel Hill, North Carolina; and Oak Ridge 
institute fo r  Science and Education, Oak Ridge, Tennessee
Radiation exposure to a breast feeding infant was estimated when 
the mother underwent a nuclear medicine procedure using 201TL 
Methods: A iactating mother was administered 111 MBq of 201TI for 
a brain scan. Breast milk samples were collected over a period of 
three days, and the rate of 201TI secretion was determined. The 
infant was not breast fed during that time. Based on our data, we 
determined the time-activity function for radioactivity in the breast 
milk. From these data, and assuming an intake of 1000 ml/dayt we 
calculated the fraction of administered activity that might be taken in 
by the infant. We also calculated the intake assuming breastfeeding 
delays of 2, 24, 48, 72, 96 and 500 hr. Results: We calculated the 
radiation dose to various organs and the effective dose to an infant 
and a 1-yr-old for breastfeeding delays of 2 to 500 hr. The effective 
dose to a 1 -yr-old from an administration of 111 MBq of 201T! to the 
mother ranged from 0.90 mSv to 0.00072 mSv, and the effective 
dose to a newborn ranged from 1.6 mSv to 0.0013 mSv depending 
on delay time. Conclusion: Our estimates of radiation exposure to 
an infant from breastfeeding indicate that in this case, a 1-yr-old 
would have received less than the NCRP’s proposed limit on annual 
effective dose to members of the general public of 1 mSv with a 48- 
hr deiay and no restrictions on holding the child. A newborn would 
have received less than the proposed Infrequent exposure limit of 5 
mSv without any delay or restrictions in breastfeeding.
Key Words: breast milk; radiation dose; radioactivity 
J Nucl Med 1996; 37:2079-2082
I t  is generally not desirable to administer radionuclides to 
patients who are breastfeeding. In those cases, however, where 
it is deemed necessary for the health o f the mother to proceed 
with a nuclear medicine study, the recommendation often is to 
stop nursing for some period of time. The ICRP recommenda­
tions (1) for cessation of breastfeeding, if  any, depend on which 
of the defined groups the radionuclide falls into. Thallium-201
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falls into group I, for which the recommendation is to stop 
nursing for a period of 3 wk. This is the most conservative 
approach, short of complete cessation of breastfeeding, from the 
viewpoint o f radiation safety. It may, however, be highly 
undesirable for many other reasons. The literature provides 
limited data on the secretion of radiopharmaceuticals in breast 
milk (2-4) .  We measured 201Tl excretion in breast milk o f a 
patient after administration o f thallous chloride for a brain scan.
MATERIALS AND METHODS
The patient was a 32-yr-oid female with a history of a brain 
tumor which had been treated with multiple surgical resections and 
radiation therapy. The patient was scheduled in the nuclear 
medicine clinic for a 201T1 brain scan which was performed with 
111 MBq (3 mCi) to evaluate for abnormal uptake which would 
indicate residual tumor and serve as a baseline for further imaging. 
At the time of the study, the patient was breastfeeding. The child 
was a normal, healthy 5-mo-old. The decision to undergo the study 
rather than to delay it to a later date was based on the strong desire 
of the patient and her family to proceed.
The mother was instructed that she should temporarily cease 
breastfeeding and use a breast pump from the time of administra­
tion of the radioactivity until we could make a further evaluation. 
No restrictions were imposed on holding her infant. Breast milk 
samples were collected by the patient at the times she would 
normally have breast fed over a period of three days beginning with 
the time of administration. Samples from each breast pumping 
were collected in 20 ml test tubes, labeled with the date and time 
of expression, and refrigerated. The samples were returned to the 
nuclear medicine clinic 3 days later. The milk samples and a 201T1 
standard were counted in a scintillation well counter. The milk 
sample results were recorded in terms of the radioactive concen­
tration (Bq/ml) and decay corrected to the time of administration. 
A total of 10 samples were collected over a period of 72 hr from the 
time of administration. The corrected radioactivity concentration is 
shown in Table 1.
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